Putting Oncology Patients at Risk Using genomic tests to personalize oncology treatment is a worthy endeavor. But when the rush to capitalize on biomedical research overcomes the rules of evidence, it's the patients who suffer.

摘要

What happened at the Duke University Institute for Genome Sciences and Policy could be the plot of a Robin Cook medical thriller - except that Cook writes fiction and the events at Duke were all too real, especially for 110 cancer patients enrolled in three clinical trials based on bogus research. The paper by a Duke research team led by principal investigators Anil Potti, MD, and Joseph R. Nevins, PhD, published in Nature Medicine in 2006 is a good place to start.